10 regulatory consultants

Alkermes, Horizon and Kyverna Therapeutics are among the companies where six of these regulatory consultants held a head of regulatory affairs or regulatory strategy title, and four of the group are based in Europe, in Basel, London, Como and Copenhagen. A drug developer choosing between FDA and EMA routes, planning a first IND or CTA, or preparing for an early regulator meeting would get the most from them.

10 professionals10 companiesData retrieved September 29, 2026

Professionals to explore

  1. Alison McGregor

    LinkedIn

    Experience: Principal Consultant Global Regulatory Affairs · Independent Regulatory Affairs Consultant to Biotech and Pharmaceutical Industry

    Since December 2019, Alison McGregor has been Principal Consultant Global Regulatory Affairs as an independent consultant to the biotech and pharmaceutical industry, and Vice President Regulatory Affairs at Crystalys Therapeutics since November 2025. Alison describes more than 25 years in pharmaceutical development and regulation, including time at the MHRA, and held Regulatory Affairs Lead - Global Strategy and Operations at ReCode Therapeutics (2023–2025) and VP Regulatory Affairs and QA at SynAgile (2022–2023). Fit for UK regulator questions.

    Is this you? Claim your profile and get paid for calls.

  2. Ben Lewis, PhD

    LinkedIn

    Experience: President and Principal · Lewis Regulatory Consulting, LLC

    Since November 2019, Ben Lewis, PhD has been President and Principal of Lewis Regulatory Consulting, LLC, after earlier stints as Principal (and President) there (2008–2011 and 2013–2018). Between those, Ben was Executive Director and Head Regulatory Affairs North America at Mitsubishi Tanabe Pharma Development America (2011–2013) and Vice President Regulatory Affairs at Kolon TissueGene, Inc. (2018–2019). Ben describes broad industry and FDA experience in development, compliance and global product registration, which fits health authority interaction questions.

    Is this you? Claim your profile and get paid for calls.

  3. Daryl DeKarske

    LinkedIn

    Experience: Biopharmaceutical Global Regulatory Affairs Strategy Consultant · RegStrat LLC

    Daryl DeKarske has been a Biopharmaceutical Global Regulatory Affairs Strategy Consultant at RegStrat LLC since April 2024. Daryl was Sr. Vice President, Head of Global Regulatory Affairs at Horizon (2022–2024), Sr. Vice President, Global Head of Regulatory Affairs and Translational Sciences at Acadia Pharmaceuticals (2017–2022) and Vice President, IM, Ophthalmology, Emerging Products and Due Diligence, Global Regulatory Affairs at Shire (2010–2017). Daryl's experience covers psychiatry, neurology and other therapeutic areas.

    Is this you? Claim your profile and get paid for calls.

  4. Emma Ungstrup

    LinkedIn

    Experience: CEO and Principal Consultant in Regulatory Development Strategy · EJConsulting

    In their own words, Emma Ungstrup shapes early Phase 1/2 global regulatory and development strategies, with more than 20 years of experience and regulatory strategy work across advanced therapies such as CAR-T, gene therapies and RNA therapeutics. Emma has been CEO and Principal Consultant in Regulatory Development Strategy at EJConsulting since April 2026, and was Senior Director, Global Regulatory Affairs, Team Lead Strategy (EU & RoW) at Genmab (2025–2026) and Senior Director, Head of European Regulatory Affairs at Kyverna Therapeutics (2024–2025).

    Is this you? Claim your profile and get paid for calls.

  5. Laurie Ridener

    LinkedIn

    Experience: Managing Principal · Erskine Mar Consulting LLC

    Laurie Ridener founded Erskine Mar Consulting LLC and has been its Managing Principal since February 2014, advising mainly small and emerging biotech companies, particularly oncology startups, on FDA strategy, IND development and early clinical execution. Laurie was Director, Senior Advisor, Global Regulatory Affairs - NDD at EMD Serono, Inc. (2010–2014), Senior Director, Clinical and Regulatory Affairs at Pervasis Therapeutics, Inc. (2006–2009) and Senior Manager, Metabolic & Endocrine Therapeutic Area at EMD Serono (2001–2006).

    Is this you? Claim your profile and get paid for calls.

  6. Lynne Ensor

    LinkedIn

    Experience: President Owner Regulatory Consultant · Ensor Pharma Biotech Consulting

    Lynne Ensor describes being an ex-FDA senior leader with more than 27 years in regulatory affairs and compliance, and has been President Owner Regulatory Consultant at Ensor Pharma Biotech Consulting since March 2025 and a Partner at ELIQUENT Life Sciences since July 2026. Lynne was Senior Global Managing Director and Vice President, Pharma Biotech Consulting at NSF (2024–2025), and at Parexel held Senior Vice President, Head of Global Strategic Compliance Consulting (2022–2024). The pick for compliance questions seen from the FDA side.

    Is this you? Claim your profile and get paid for calls.

  7. Michaela Katharina Nahler

    LinkedIn

    Experience: Founder & Head of Regulatory Affairs Consulting · Nahler RA Consulting | Basel, Switzerland

    Michaela Katharina Nahler has been Founder & Head of Regulatory Affairs Consulting at Nahler RA Consulting since July 2022, after Senior Director, Head of Regulatory Affairs Europe at Urovant Sciences International GmbH (2021–2022). Michaela was also Director, Regulatory Affairs Europe at Arvelle Therapeutics (2020–2021) and Head, Global Labeling & Global Regulatory Affairs at Actelion (2016–2019), and describes building and leading regulatory affairs functions across Europe and guiding therapies through FDA, EMA, MHRA and Swissmedic. Fit for European filings.

    Is this you? Claim your profile and get paid for calls.

  8. Natalie Thomas

    LinkedIn

    Experience: Founder and Principal Consultant · Ramp Regulatory

    Natalie Thomas founded Ramp Regulatory in September 2023 and is its Principal Consultant, while also a Principal Consultant at Scendea since October 2023. Natalie was Director and Principal Consultant at Scendea (2020–2023) and at Clinical Network Services (CNS) Pty Ltd (2019–2020) and a Consultant Editor at TOPRA (2014–2023), with more than 17 years in non-clinical and clinical development and regulatory strategy. Good for questions on pre-market development expectations in the EU, US and UK.

    Is this you? Claim your profile and get paid for calls.

  9. Paola Tocchetti

    LinkedIn

    Experience: Global Regulatory Strategy Advisor (EU & US) · Paola Tocchetti Consulting

    Based in Italy, Paola Tocchetti has been Global Regulatory Strategy Advisor (EU & US) at Paola Tocchetti Consulting since July 2026, after SVP, Head of Global Regulatory Affairs at Aptuit (Verona) Srl, an EVOTEC Company (2022–2026). Paola was also VP, Head of Regulatory Affairs at Aptuit (2021–2022), in Global Regulatory EU at ITALFARMACO S.P.A. (2019–2021) and Chief Operation Officer at Dipharma SA (2016–2019), and names EMA, FDA and global pathways as focus areas. Suits combined EU and US strategy questions.

    Is this you? Claim your profile and get paid for calls.

  10. Stephen Boyer

    LinkedIn

    Experience: Principal Consultant · Regulatory Science Insights, LLC

    Stephen Boyer has been Principal Consultant at Regulatory Science Insights, LLC since August 2025, after Vice President, Head of Regulatory Strategy at Alkermes (2023–2025). Stephen also held Vice President, Head of Regulatory Affairs and Quality at Palleon Pharmaceuticals (2022–2023) and LogicBio Therapeutics (2021–2022), and lists IND, CTA, Orphan Drug, PIP, PSP and China CTA submissions across small molecule, biologic and gene therapy programs. The clearest fit for early development submissions.

    Is this you? Claim your profile and get paid for calls.

Choose the right perspective

For an FDA-first plan, Stephen Boyer and Laurie Ridener focus on IND and early development work, Ben Lewis, PhD on interactions with health authorities, and Lynne Ensor brings an FDA background to compliance questions. For EU and UK routes, pick one of the four based in Europe (Michaela Katharina Nahler, Natalie Thomas, Paola Tocchetti or Emma Ungstrup) or Alison McGregor, who has MHRA experience. Emma Ungstrup suits advanced therapies, Laurie Ridener oncology startups and Daryl DeKarske psychiatry and neurology programs.

Questions to take into the conversation

  1. 01When does it make sense to seek FDA and EMA advice in parallel rather than one after the other?
  2. 02What does a regulator expect in the first IND or CTA package for a small biotech's lead program?
  3. 03How do orphan drug and pediatric plan requirements change a submission timeline?

About this directory

This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.

Other perspectives in Pharmaceuticals